Published on 14 Dec 2023 on Zacks via Yahoo Finance
Editas Medicine, Inc. EDIT announced entering into a licensing agreement with Vertex Pharmaceuticals VRTX for the development of the latter’s new sickle cell disease (SCD) gene therapy, Casgevy.
Per the terms of the agreement, Vertex will receive a non-exclusive license to utilize Editas’ Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, including Casgevy (exagamglogene autotemcel [exa-cel]).
The Cas9 gene editing tool will provide Vertex access to a broad range of genetic mutations, which makes it possible to develop innovative gene-editing medicines with a novel mechanism of action.